Stéphane Roueff
Impact in
- Nephrology top 2%
- Renal Diseases and Glomerulopathies
- Chronic Kidney Disease and Diabetes
- Dialysis and Renal Disease Management
-
- COVID-19 Clinical Research Studies
Papers in
-
- Dialysis and Renal Disease Management 4
- Chronic Kidney Disease and Diabetes 2
- Renal Diseases and Glomerulopathies 2
- Parathyroid Disorders and Treatments 1
-
- Cardiovascular Effects of Exercise 1
- Co-authors
- Dominique C. Pagniez (2 shared papers)Éric Boulanger (2 shared papers)Philippe Dequiedt (2 shared papers)Olivier P. Moranne (1 shared paper)Didier Roumilhac (1 shared paper)David Launay (1 shared paper)Céline Narjoz (1 shared paper)D Droz (1 shared paper)
In The Last Decade
Stéphane Roueff
18 papers receiving 635 citations
Stéphane Roueff's Hit Papers
Peers
Comparison fields: 5 of 64
- Nephrology 323
- Infectious Diseases 94
- Hematology 55
- Medical Terminology 1
- Emergency Medical Services 22
Countries citing papers authored by Stéphane Roueff
This map shows the geographic impact of Stéphane Roueff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stéphane Roueff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stéphane Roueff more than expected).
Fields of papers citing papers by Stéphane Roueff
This network shows the impact of papers produced by Stéphane Roueff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stéphane Roueff. The network helps show where Stéphane Roueff may publish in the future.
Co-authors
The 25 scholars most cited alongside Stéphane Roueff, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial Hit paper breakdown → | 2023 | 185 |
| 2 | Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial Hit paper breakdown → | 2023 | 160 |
| 3 | 2020 | 110 | |
| 4 | 2019 | 35 | |
| 5 | 2002 | 29 | |
| 6 | 2018 | 23 | |
| 7 | 2023 | 22 | |
| 8 | 1999 | 21 | |
| 9 | 2003 | 19 | |
| 10 | 2021 | 15 | |
| 11 | 2008 | 13 | |
| 12 | 2021 | 9 | |
| 13 | 2024 | 5 | |
| 14 | 2023 | 5 | |
| 15 | 2024 | 4 | |
| 16 | [Management of atherosclerotic renal artery stenoses]. | 2002 | 2 |
| 17 | 2020 | 1 | |
| 18 | 2006 | 1 | |
| 19 | 2025 | 0 |
About Stéphane Roueff
Stéphane Roueff is a scholar working on Nephrology, Cardiology and Cardiovascular Medicine, Oncology, Pulmonary and Respiratory Medicine and Infectious Diseases, having authored 19 papers that have together received 659 indexed citations. Recurring topics across this work include Dialysis and Renal Disease Management (4 papers), Chronic Kidney Disease and Diabetes (2 papers), Renal Diseases and Glomerulopathies (2 papers), COVID-19 Clinical Research Studies (1 paper), Kidney Stones and Urolithiasis Treatments (1 paper), Cardiovascular Effects of Exercise (1 paper), Parathyroid Disorders and Treatments (1 paper) and Cardiovascular and exercise physiology (1 paper). The work is most often cited by research in Nephrology (323 citations), Infectious Diseases (94 citations), Hematology (55 citations), Medical Terminology (1 citation) and Emergency Medical Services (22 citations). Stéphane Roueff has collaborated with scholars based in France, Israel and Latvia. Frequent co-authors include Dominique C. Pagniez, Éric Boulanger, Philippe Dequiedt, Olivier P. Moranne, Didier Roumilhac, David Launay, Céline Narjoz, D Droz, D. Fleury and Nicolas Pallet. Their work appears in journals such as Clinical Nephrology, Kidney International, The Lancet, Journal of Nephrology and EBioMedicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.